Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech company dedicated to improving outcomes for patients with coronary and peripheral artery dis...
Zymo Research, a global leader in genomics tools, announced the launch of Zymo Services, a dedicated portfolio of end-to-end next-generation sequencing (...
Twelve-month findings showed improvement in Composite Unified Huntington's Disease Rating Scale (cUHDRS) scores from baseline of +0.38, compared to an ex...
First Foundation Labs (1FL), a life sciences AI company pioneering clinical and translational reasoning spun out of Luma Group, announced a collaboration...
Integrated, push-button oncology research workflows give customers a simplified path from library prep through DRAGEN™-powered secondary analysis ...
T-CURX leverages Pantherna’s deep expertise and proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovati...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ch...
WFI manufacturing and other capabilities support for pharmaceutical innovation, GLP‑1 therapies, and medical devices. ILC Dover, an Ingersoll Rand bus...
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obef...
Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resist...
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Lev...
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Genera...
Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inha...
Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, unders...
© 2026 Biopharma Boardroom. All Rights Reserved.
